Surrey Leads Europe in Alzheimer’s Prevention Drug Trial
Landmark Trial Comes to Our Community
Surrey and Borders Partnership NHS Foundation Trust has achieved a significant milestone by becoming the first NHS trust in Europe to participate in a major Alzheimer’s prevention trial. This pioneering initiative positions our region at the forefront of dementia research and means local residents now have access to cutting-edge medical research without needing to travel internationally.
The trial, which is examining a promising new drug called Trontinemab, marks a fundamental shift in how the medical community approaches Alzheimer’s disease. Rather than waiting for symptoms to appear—as has been the case for decades—researchers are testing whether they can intervene earlier, potentially preventing or significantly delaying the onset of cognitive decline in at-risk individuals.
For those living across Surrey, from Guildford to Woking, Dorking to East Horsley, and surrounding areas in north east Hampshire, this represents a remarkable opportunity. The trust is actively recruiting participants from anywhere in the UK, meaning your postcode doesn’t exclude you from potentially life-changing medical intervention. The international trial aims to recruit 1,600 healthy adults aged 55 to 80, with researchers using advanced blood tests to identify those most likely to benefit from participation.
Who Can Take Part and What It Means
Understanding the eligibility criteria is straightforward. Surrey and Borders Partnership NHS Foundation Trust is particularly keen to involve people aged 55 to 80 who don’t currently show signs of dementia but may be at higher genetic or biological risk. Researchers will conduct initial blood tests to determine whether you’re likely to benefit from the trial before any commitment is required.
Professor Ramin Nilforooshan, the consultant psychiatrist leading the trial at the trust, emphasises the paradigm shift this represents. “For decades, our research has focused on treating Alzheimer’s after symptoms have already appeared,” he explains. “This trial asks a fundamentally different question: can we act earlier, before cognitive changes begin?”
The drug itself targets beta amyloid, a sticky protein that accumulates in the spaces between brain cells in Alzheimer’s disease. By intervening at this biological level before symptoms emerge, researchers hope to prevent or delay the progression of dementia. For families in Horsley, Woking, and beyond who have watched loved ones struggle with Alzheimer’s, the potential implications are profound. Being part of this research could offer both personal health insights and contribute to medical breakthroughs that affect millions worldwide.
Local Impact and Next Steps for Residents
With approximately 982,000 people living with dementia in the UK today, and Alzheimer’s accounting for 60-80% of all dementia cases, this trial addresses one of our nation’s most pressing health challenges. For our Surrey community, the opportunity to participate in European-leading research represents both hope and practical action.
If you’re aged 55-80 and interested in learning whether you might be eligible for the trial, contact Surrey and Borders Partnership NHS Foundation Trust for information about blood testing and participation. The trust can provide details about what involvement entails, the time commitment required, and how your participation could contribute to potentially life-saving discoveries.
Beyond individual participation, this trial underscores why local healthcare infrastructure matters. Community-based medical research keeps our region connected to breakthrough innovations and ensures cutting-edge treatments are accessible locally rather than requiring travel to distant specialist centres. For residents across Guildford, Dorking, and surrounding areas, staying informed about opportunities like this empowers you to take proactive steps regarding your long-term health. Share this information with friends and family members who might be eligible—participating in research today could shape healthier futures for generations to come in our community.
Source: Surrey and Borders trust joins Alzheimer’s prevention drug trial
